Chapman Andrew R, Lee Kuan Ken, McAllister David A, Cullen Louise, Greenslade Jaimi H, Parsonage William, Worster Andrew, Kavsak Peter A, Blankenberg Stefan, Neumann Johannes, Sörensen Nils A, Westermann Dirk, Buijs Madelon M, Verdel Gerard J E, Pickering John W, Than Martin P, Twerenbold Raphael, Badertscher Patrick, Sabti Zaid, Mueller Christian, Anand Atul, Adamson Philip, Strachan Fiona E, Ferry Amy, Sandeman Dennis, Gray Alasdair, Body Richard, Keevil Brian, Carlton Edward, Greaves Kim, Korley Frederick K, Metkus Thomas S, Sandoval Yader, Apple Fred S, Newby David E, Shah Anoop S V, Mills Nicholas L
BHF Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, Scotland.
Institute of Health and Wellbeing, University of Glasgow, Glasgow, Scotland.
JAMA. 2017 Nov 21;318(19):1913-1924. doi: 10.1001/jama.2017.17488.
High-sensitivity cardiac troponin I testing is widely used to evaluate patients with suspected acute coronary syndrome. A cardiac troponin concentration of less than 5 ng/L identifies patients at presentation as low risk, but the optimal threshold is uncertain.
To evaluate the performance of a cardiac troponin I threshold of 5 ng/L at presentation as a risk stratification tool in patients with suspected acute coronary syndrome.
Systematic search of MEDLINE, EMBASE, Cochrane, and Web of Science databases from January 1, 2006, to March 18, 2017.
Prospective studies measuring high-sensitivity cardiac troponin I concentrations in patients with suspected acute coronary syndrome in which the diagnosis was adjudicated according to the universal definition of myocardial infarction.
The systematic review identified 19 cohorts. Individual patient-level data were obtained from the corresponding authors of 17 cohorts, with aggregate data from 2 cohorts. Meta-estimates for primary and secondary outcomes were derived using a binomial-normal random-effects model.
The primary outcome was myocardial infarction or cardiac death at 30 days. Performance was evaluated in subgroups and across a range of troponin concentrations (2-16 ng/L) using individual patient data.
Of 11 845 articles identified, 104 underwent full-text review, and 19 cohorts from 9 countries were included. Among 22 457 patients included in the meta-analysis (mean age, 62 [SD, 15.5] years; n = 9329 women [41.5%]), the primary outcome occurred in 2786 (12.4%). Cardiac troponin I concentrations were less than 5 ng/L at presentation in 11 012 patients (49%), in whom there were 60 missed index or 30-day events (59 index myocardial infarctions, 1 myocardial infarction at 30 days, and no cardiac deaths at 30 days). This resulted in a negative predictive value of 99.5% (95% CI, 99.3%-99.6%) for the primary outcome. There were no cardiac deaths at 30 days and 7 (0.1%) at 1 year, with a negative predictive value of 99.9% (95% CI, 99.7%-99.9%) for cardiac death.
Among patients with suspected acute coronary syndrome, a high-sensitivity cardiac troponin I concentration of less than 5 ng/L identified those at low risk of myocardial infarction or cardiac death within 30 days. Further research is needed to understand the clinical utility and cost-effectiveness of this approach to risk stratification.
高敏心肌肌钙蛋白I检测广泛用于评估疑似急性冠脉综合征的患者。心肌肌钙蛋白浓度低于5 ng/L可将就诊时的患者识别为低风险,但最佳阈值尚不确定。
评估就诊时心肌肌钙蛋白I阈值为5 ng/L作为疑似急性冠脉综合征患者风险分层工具的性能。
对2006年1月1日至2017年3月18日期间的MEDLINE、EMBASE、Cochrane和科学网数据库进行系统检索。
测量疑似急性冠脉综合征患者高敏心肌肌钙蛋白I浓度的前瞻性研究,其诊断根据心肌梗死的通用定义进行判定。
系统评价确定了19个队列。从17个队列的相应作者处获得个体患者水平的数据,2个队列提供汇总数据。使用二项式正态随机效应模型得出主要和次要结局的meta估计值。
主要结局为30天时的心肌梗死或心源性死亡。使用个体患者数据在亚组以及一系列肌钙蛋白浓度范围(2 - 16 ng/L)内评估性能。
在检索到的11845篇文章中,104篇进行了全文审查,纳入了来自9个国家的19个队列。在纳入荟萃分析的22457例患者中(平均年龄62岁[标准差15.5];n = 9329例女性[41.5%]),主要结局发生在2786例(12.4%)患者中。11012例患者(49%)就诊时心肌肌钙蛋白I浓度低于5 ng/L,其中有60例漏诊的首次或30天事件(59例首次心肌梗死,1例30天时心肌梗死,30天时无心脏死亡)。这导致主要结局的阴性预测值为99.5%(95%CI,99.3% - 99.6%)。30天时无心脏死亡,1年时有7例(0.1%),心脏死亡的阴性预测值为99.9%(95%CI,99.7% - 99.9%)。
在疑似急性冠脉综合征患者中,高敏心肌肌钙蛋白I浓度低于5 ng/L可识别出30天内心肌梗死或心源性死亡风险较低的患者。需要进一步研究以了解这种风险分层方法的临床实用性和成本效益。